1. Home
  2. EAD vs MIRM Comparison

EAD vs MIRM Comparison

Compare EAD & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allspring Income Opportunities Fund

EAD

Allspring Income Opportunities Fund

HOLD

Current Price

$6.59

Market Cap

394.7M

Sector

Finance

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$93.06

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EAD
MIRM
Founded
2003
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
394.7M
5.4B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
EAD
MIRM
Price
$6.59
$93.06
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
$114.67
AVG Volume (30 Days)
155.9K
698.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
8.91%
N/A
EPS Growth
N/A
74.59
EPS
N/A
N/A
Revenue
N/A
$19,138,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$21.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.89
$36.88
52 Week High
$7.18
$109.28

Technical Indicators

Market Signals
Indicator
EAD
MIRM
Relative Strength Index (RSI) 32.73 48.00
Support Level N/A $72.17
Resistance Level $6.89 $107.51
Average True Range (ATR) 0.07 4.04
MACD -0.02 -0.56
Stochastic Oscillator 23.52 30.40

Price Performance

Historical Comparison
EAD
MIRM

About EAD Allspring Income Opportunities Fund

Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: